- Home
- TBPH vs AVTX Comparison
TBPH vs AVTX Comparison
Compare TBPH & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TBPH | AVTX |
|---|---|---|
| Founded | 2013 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 908.9M | 956.7M |
| IPO Year | 2013 | 2015 |
Fundamental Metrics
Financial Performance| Metric | TBPH | AVTX |
|---|---|---|
| Price | $16.91 | $18.80 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 8 |
| Target Price | $18.40 | ★ $40.57 |
| AVG Volume (30 Days) | 905.3K | ★ 1.9M |
| Earning Date | 05-04-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 279.13 | 72.07 |
| EPS | ★ N/A | N/A |
| Revenue | $15,386,000.00 | ★ $27,813,137.00 |
| Revenue This Year | $8.46 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 2312.27 |
| 52 Week Low | $10.82 | $4.81 |
| 52 Week High | $21.03 | $24.27 |
Technical Indicators
Market Signals| Indicator | TBPH | AVTX |
|---|---|---|
| Relative Strength Index (RSI) | 52.35 | 57.57 |
| Support Level | $16.12 | $13.13 |
| Resistance Level | $17.21 | $19.06 |
| Average True Range (ATR) | 0.22 | 1.35 |
| MACD | -0.04 | 0.13 |
| Stochastic Oscillator | 1.75 | 55.84 |
Price Performance
Historical ComparisonAbout TBPH Theravance Biopharma Inc.
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.